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ABSTRACT
Milk thistle (Silybum marianum) is a popular herbal product
used for hepatoprotection and chemoprevention. Two com-
mercially available formulations are the crude extract, silymarin,
and the semipurified product, silibinin. Silymarin consists of at
least seven flavonolignans, of which the most prevalent are the
diastereoisomers silybin A and silybin B; silibinin consists only
of silybin A and silybin B. Based on a recent clinical study
showing an interaction between a silymarin product and the
CYP2C9 substrate losartan, the CYP2C9 inhibition properties
of silybin A and silybin B and corresponding regioisomers,
isosilybin A and isosilybin B, were evaluated using human liver
microsomes (HLMs), recombinant CYP2C9 (rCYP2C9) en-
zymes, and the clinically relevant probe, (S)-warfarin. Silybin B
was the most potent inhibitor in HLMs, followed by silybin A,
isosilybin B, and isosilybin A (IC50 of 8.2, 18, 74, and 100 M,
respectively). Next, silybin A and silybin B were selected for
further characterization. As with HLMs, silybin B was more
potent than silybin A toward rCYP2C9*1 (6.7 versus 12 M),
rCYP2C9*2 (9.3 versus 19 M), and rCYP2C9*3 (2.4 versus 9.3
M). Using a matrix of five substrate (1–15 M) and six inhibitor
(1–80 M) concentrations and HLMs, both diastereoisomers
inhibited (S)-warfarin 7-hydroxylation in a manner described
best by a mixed-type inhibition model (Ki values of 4.8 and 10
M for silybin B and silybin A, respectively). These observa-
tions, combined with the high systemic silibinin concentrations
(5–75 M) achieved in a phase I study involving prostate
cancer patients, prompt clinical evaluation of a potential war-
farin-milk thistle interaction.
Milk thistle [Silybum marianum (L.) Gaertn.] is a resilient
and sometimes noxious plant that has been valued for its
medicinal qualities for more than 2000 years (Kroll et al.,
2007; Post-White et al., 2007). In modern herbal compendia,
milk thistle is used to self-treat hepatic disorders, including
hepatitis C and cirrhosis, and as a hepatoprotectant, partic-
ularly for mushroom poisoning. Milk thistle is available
mainly as an extract prepared from the seeds of the plant.
The two most common commercial preparations are termed
silymarin and silibinin. Silymarin, a crude extract, is a complex
mixture of at least seven flavonolignans and one flavonoid
(taxifolin) (Davis-Searles et al., 2005; Kroll et al., 2007). The
most abundant flavonolignans are the diastereoisomers sily-
bin A and silybin B (Fig. 1). The diastereoisomers isosilybin
A and isosilybin B (Fig. 1) also are present and are regioiso-
mers of silybin A and silybin B. The remaining three flavono-
lignans are silychristin, isosilychristin, and silydianin, all of
which are constitutional isomers of the aforementioned com-
pounds (Davis-Searles et al., 2005). Silibinin is a semipurified
extract, representing approximately a 1:1 mixture of silybin A
and silybin B. Because silymarin and silibinin are mixtures of
compounds derived from a natural source, batch-to-batch vari-
ation in bioactive ingredient composition occurs, which can con-
found the interpretation of study results (Kroll et al., 2007).
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Fortuitously, methods have been developed to isolate and purify
gram quantities of each flavonolignan from milk thistle extract,
permitting delineation of the disposition and action of single
constituents (Kim et al., 2001; Graf et al., 2007).
Milk thistle has garnered attention since the 1990s for its
chemopreventive properties, particularly for prostate cancer
(Agarwal et al., 2006; Gazák et al., 2007; Kroll et al., 2007).
With the advent of single components from silymarin, the
antiproliferative effects of each flavonolignan, as well as
those of silymarin and silibinin, were compared using human
prostate cancer cell lines; at concentrations ranging from 15
to 90 M, isosilybin B was consistently the most potent of all
the individual components and mixtures examined (Davis-
Searles et al., 2005). In rodent models of prostate cancer,
dietary feeding of silymarin and silibinin has been shown,
respectively, to decrease the incidence of 3,2-dimethyl-4-
aminobiphenyl-induced prostatic adenocarcinoma (Kohno
et al., 2005) and to inhibit prostate tumor growth (Ramasamy
and Agarwal, 2008; Singh et al., 2008). The latter studies set
the target systemic concentration of silibinin at 10 to 15 M.
Clinical studies have indicated that both silymarin and
silibinin have poor oral bioavailability because of extensive
first-pass conjugation via UDP-glucuronosyl transferases
and sulfotransferases (Flaig et al., 2007; Schrieber et al.,
2008; Wen et al., 2008). As such, at typical “doses,” systemic
concentrations of unconjugated flavonolignans 1 M are
rarely achieved. The first study to demonstrate systemic
concentrations of unconjugated silibinin in the purported
therapeutic range was a phase I dose escalation study involv-
ing prostate cancer patients (Flaig et al., 2007). These pa-
tients were administered 2.5 to 20 g/day of a silibinin-phos-
phatidylcholine complex (Siliphos), which has improved
absorption characteristics and presumably improved bio-
availability compared with noncomplexed silibinin (Flaig et
al., 2007). Average peak plasma concentrations of unconju-
gated silibinin ranged from 5 to 75 M. Moreover, these high
doses were well tolerated, and several patients experienced
prolonged stable disease, prompting a phase II study that is
currently underway.
Herbal products often are taken concomitantly with med-
ications, which could potentially lead to dangerous interac-
tions (Hu et al., 2005; Wu et al., 2009). Clinical studies
involving milk thistle extracts to date have shown minimal to
no drug interaction liability, at least with drugs that are
considered probe substrates for CYP1A2, CYP2D6, CYP2E1,
and CYP3A and the efflux transporter P-glycoprotein (Gur-
ley et al., 2004, 2006a,b, 2008). A caveat to these studies is
that a low total daily “dose” (1 g) of extract (silymarin) was
given, which is much less than that postulated to have clin-
ical benefit, at least for prostate cancer. However, a recent
healthy volunteer study demonstrated an interaction be-
tween the antihypertensive agent and CYP2C9/CYP3A sub-
strate losartan and silymarin, the latter of which was given
as a low total daily dose (420 mg) (Han et al., 2009). Relative
to placebo, in CYP2C9*1 carriers, silymarin decreased the
area under the curve ratio of the CYP2C9-mediated active
metabolite, E-3174, to that of losartan, by 50% (p  0.05),
suggesting inhibition of hepatic CYP2C9 by one or more
components of silymarin. These observations, coupled with
the high systemic concentrations observed in the dose esca-
lation study, prompted a systematic evaluation of the inhib-
itory effects of individual components from silymarin on the
CYP2C9-mediated metabolism of another clinically relevant
substrate, (S)-warfarin, the more pharmacologically active
enantiomer of the widely prescribed oral anticoagulant war-
farin. In particular, the inhibitory potencies of four key fla-
vonolignans (silybin A, silybin B, isosilybin A, and isosilybin
B) toward (S)-warfarin 7-hydroxylation were compared using
human liver microsomes and recombinant CYP2C9 enzymes.
To the authors’ knowledge, this work represents the first
evaluation of the drug interaction liability of single, purified
constituents from milk thistle.
Materials and Methods
Chemicals and Reagents
Human liver microsomes (HLMs) (pooled from 50 donors, mixed
gender) were purchased from XenoTech, LLC (Lenexa, KS). Baculo-
virus insect cell-expressed CYP2C9*1, CYP2C9*2, CYP2C9*3 (sup-
plemented with cDNA-expressed reductase but not cytochrome b5),
tienilic acid, and 7-hydroxywarfarin were purchased from BD
Biosciences (San Jose, CA). (S)-Warfarin, chlorowarfarin, sulfa-
phenazole, NADPH, and high-performance liquid chromatography-
grade water, methanol, ammonium acetate, and 1-propanol were
purchased from Sigma-Aldrich (St. Louis, MO). Silybin A, silybin B,
isosilybin A, and isosilybin B were isolated from milk thistle extract
as described previously (Graf et al., 2007); all flavonolignans were
97% pure as determined by high-performance liquid chromatogra-
phy.
Evaluation of Silymarin Flavonolignans as Inhibitors of
CYP2C9 Activity
The inhibitory effects of each flavonolignan on (S)-warfarin 7-hy-
droxylation were evaluated using pooled HLMs and recombinant
CYP2C9 (rCYP2C9). (S)-Warfarin and sulfaphenazole were dis-
solved in methanol to yield working concentrations of 10 and 1 mM,
respectively. Each flavonolignan was dissolved in methanol to yield
a working concentration of 50 mM. NADPH was dissolved fresh in
potassium phosphate buffer (0.1 M, pH 7.4) to yield a working con-
centration of 4 mM. Incubation mixtures were prepared in 96-well
plates. Under all experimental conditions, the amount of 7-hydroxy-
warfarin formed was linear with respect to incubation time and
mass/amount of microsomal protein or rCYP2C9 (data not shown).
Initial Testing. Incubation mixtures consisted of HLMs (0.1
mg/ml microsomal protein), (S)-warfarin (4 M), flavonolignan (1,
10, and 100 M), and potassium phosphate buffer (100 mM, pH 7.4).
As a positive control for CYP2C9 inhibition, incubation mixtures
contained sulfaphenazole (1 M) in place of flavonolignan. Control
incubation mixtures contained 0.75% methanol (v/v) in place of fla-
vonolignan/sulfaphenazole. The plates were placed on a dry heat
block, and the mixtures were equilibrated for 5 min at 37°C before
Fig. 1. Structures of the four selected flavonolignans from milk thistle.
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initiation of the reactions with NADPH (1 mM final concentration) to
yield a final volume of 200 l. After 30 min, the reactions were
quenched with 400 l of cold methanol containing 3.33 nM chloro-
warfarin as the internal standard. After centrifugation (1350g for 10
min at 4°C), the supernatant (8 l) was analyzed for 7-hydroxywar-
farin by LC-MS/MS (described below).
Ki Determination for Silybin A and Silybin B Using HLMs.
Incubation mixtures were prepared in a manner similar to that
described above using a 5  6 matrix of substrate (1–15 M) and
flavonolignan (1–80 M) concentrations. The reaction mixtures were
processed further and analyzed for 7-hydroxywarfarin as described
above.
IC50 Determination for Silybin A and Silybin B Using
rCYP2C9 Enzymes. Incubation mixtures consisting of rCYP2C9
(12.5 pmol/ml), (S)-warfarin (4 M), flavonolignan (0.5–100 M), and
potassium phosphate buffer were equilibrated for 5 min at 37°C before
initiation of the reactions with NADPH. After 30 (rCYP2C9*1 and
rCYP2C9*2) or 60 (rCYP2C9*3) min, the reactions were quenched and
processed as described above.
Testing Of Silybin A and Silybin B as Mechanism-Based
Inhibitors of CYP2C9 Using HLMs. IC50 shift experiments
(Obach et al., 2007) were used to determine whether silybin A and
silybin B are mechanism-based inhibitors of hepatic CYP2C9 activ-
ity. Primary incubation mixtures consisting of HLMs (1 mg/ml),
flavonolignan (0.1–1000 M), and potassium phosphate buffer were
equilibrated for 5 min at 37°C before initiation of the reactions with
NADPH. Control primary reaction mixtures were identical except
that NADPH was absent. As a positive control for mechanism-based
inhibition, incubation mixtures contained tienilic acid (1.0–500 M)
in place of flavonolignan. After 30 min, an aliquot (20 l) was re-
moved and diluted 10-fold into a secondary incubation mixture con-
taining (S)-warfarin (4 M) and NADPH (1 mM). After an additional
30 min, the secondary reactions were quenched and processed as
described above.
Analysis of Microsomal Incubations for 7-Hydroxywarfarin
7-Hydroxywarfarin was quantified by LC-MS/MS using a solvent
delivery system (Shimadzu, Columbia, MD) and an HTC Pal ther-
mostated autosampler (LEAP Technologies, Carrboro, NC) con-
nected to an API 4000 triple quadruple mass spectrometer equipped
with a TurboSpray ion source (Applied Biosystems, Foster City, CA).
Tuning, operation, integration, and data analyses were carried out in
negative mode using multiple reaction monitoring (Analyst software
version 1.4.1; Applied Biosystems). Analytes (7-hydroxywarfarin and
chlorowarfarin) and other metabolites were separated using a Gemini
C18 column (30  2.0 mm, 5 m particle size; Phenomenex, Torrance,
CA) and a solvent flow rate of 0.75 ml/min. The initial gradient condi-
tion was 100% 10 mM ammonium acetate, which was held for 0.7 min,
and the eluent was directed to waste. From 0.7 to 4.5 min, the mobile
phase composition increased linearly to 60% methanol, and the eluent
was directed to the mass spectrometer. At 5.0 min, the eluent was
directed again to waste, and the column was flushed with 80% metha-
nol for 0.4 min. From 6.0 to 6.5 min, the system was equilibrated with
100% 10 mM ammonium acetate. Total run time, including equilibra-
tion, was 6.5 min/injection. Duplicate 10-point calibration curves for
7-hydroxywarfarin (0.2–100 nM) were constructed using the peak area
ratio of 7-hydroxywarfarin (323.063 176.8; retention time 3.34 min) to
chlorowarfarin (341.2 3 160.9; retention time 4.24 min). Interday ac-
curacy and precision ranged from 99 to 110% and from 9.0 to 12%,
respectively, for all quality controls (0.23, 1.5, and 15 pmol).
Data Analysis
Apparent IC50 Determination. Initial estimates of apparent
IC50 values were derived from linear regression of the velocity
versus natural logarithm of flavonolignan concentration data.
Apparent IC50 values were determined by fitting eq. 1 with un-




1   SIC50
(1)
where S denotes the concentration of (S)-warfarin, and v0 and v
denote the velocity of 7-hydroxywarfarin formation in the absence
and presence of flavonolignan, respectively.
Apparent Ki Determination. Initial estimates of apparent Km
and Vmax were derived from Eadie-Hofstee plots of the velocity ver-
sus velocity/[substrate] data in the absence of flavonolignan. Initial
estimates of apparent Ki values were derived from Dixon plots of
velocity1 versus flavonolignan concentration data. Kinetic param-
eters (Km, Vmax, and Ki) were obtained by fitting eqs. 2 to 4 for a
unienzyme system with untransformed data:
Competitive v 
Vmax  S








Km1   IKi S1  IKi
(4)
where S again denotes the concentration of (S)-warfarin, I denotes
the concentration of inhibitor, and  (eq. 4) denotes a parameter to
describe the affinity change of the enzyme-substrate and enzyme-
inhibitor complexes (Geng, 2003). When  	 1, eq. 4 simplifies to the
pure noncompetitive inhibition model (eq. 3); when  is very large
(approaches infinity), eq. 4 simplifies to the pure competitive inhibi-
tion model (eq. 2). The best-fit equation was assessed from visual
inspection of the observed versus predicted data, randomness of the
residuals, Akaike information criteria, and S.E.s of the parameter
estimates. Apparent intrinsic clearance (Clint) was calculated as the
ratio of Vmax to Km.
Statistical Analysis
All statistical analyses were carried out using SigmaStat (version
3.5; Systat Software, Inc., San Jose, CA). Data are presented as
means 
 S.D. of triplicate determinations, unless indicated other-
wise. Concentration-dependent inhibition of each flavonolignan in
HLMs was evaluated by one-way analysis of variance (ANOVA); post
hoc comparisons were made using Tukey’s test when an overall
difference resulted (p  0.05). Enzyme kinetic parameters are pre-
sented as estimates 
 S.E. Statistical differences between the cal-
culated IC50 for silybin A and silybin B within an enzyme source was
evaluated by a Student’s t test of two independent samples; p  0.05
was considered significant. Statistical differences between the cal-
culated IC50 for a given inhibitor among enzyme sources was evalu-
ated by one-way ANOVA; post hoc comparisons were made using
Tukey’s test when an overall difference resulted (p  0.05).
Results
Selected Flavonolignans Differentially Inhibit CYP2C9-
Mediated Warfarin Metabolism. Each flavonolignan inhib-
ited the 7-hydroxylation of (S)-warfarin in a concentration-de-
pendent manner, with the diastereoisomer pair silybin A and
silybin B showing greater potency than their regioisomer coun-
terparts isosilybin A and isosilybin B (Fig. 2). Within each
diastereoisomer pair, the B forms were slightly more potent
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than the A forms. As reflected by the IC50 values, silybin B
was the most potent of the flavonolignans tested, followed by
silybin A, isosilybin B, and isosilybin A (Table 1). Isosilybin A
and isosilybin B were not evaluated further because of the
relative lack of inhibitory potency.
Silybin B Is a More Potent Inhibitor of CYP2C9-Me-
diated Warfarin Metabolism than Silybin A. The appar-
ent Ki for silybin A and silybin B toward (S)-warfarin 7-hy-
droxylation was determined using a 5  6 matrix of
substrate-inhibitor concentrations and HLMs (Fig. 3). The
simple linear mixed-type inhibition model (eq. 4) best de-
scribed the data for both silybin A and silybin B. In the
absence of inhibitor, 7-hydroxywarfarin formation was con-
sistent with classic Michaelis-Menten unienzyme kinetics, as
evidenced by linear Eadie-Hofstee plots (data not shown).
The Km and Vmax of 7-hydroxywarfarin formation were, re-
spectively, 4.0 
 0.5 M and 7.7 
 0.5 pmol/min/mg protein
(silybin A) or 3.4 
 0.4 M and 9.1 
 0.6 pmol/min/mg
protein (silybin B). Clint values were 1.9 and 2.7 l/min/mg,
respectively. The Ki for silybin A was twice that for silybin
B (Fig. 3). The  values for silybin A and silybin B were 5
and 8, respectively. As observed with HLMs, silybin B was
more potent than silybin A with all recombinant enzyme
variants (Fig. 4). At the lowest flavonolignan concentration
tested, the velocity for CYP2C9*1 was approximately twice
that of CYP2C9*2, which was approximately twice that of
CYP2C9*3. For a given inhibitor, the calculated IC50 value
for CYP2C9*3 was significantly lower than that for HLM,
CYP2C9*1, and CYP2C9*2 (Table 1).
Silybin A and Silybin B Do Not Appear to Be Mech-
anism-Based Inhibitors of (S)-Warfarin 7-Hydroxyla-
tion. IC50 shift experiments with HLMs were carried out to
determine whether silybin A and silybin B are mechanism-
based inhibitors of hepatic CYP2C9. When NADPH was ab-
sent from the primary incubation mixture, the calculated
IC50 values for each flavonolignan agreed with those from
initial experiments (Table 1). When NADPH was present in
the primary reaction mixture, IC50 values remained un-
changed (Fig. 5). The calculated IC50 value for the positive
control, tienilic acid, shifted from 12 
 0.9 M in the absence
of NADPH to 1.7 
 0.1 M in the presence of NADPH (Fig. 5,
inset).
Discussion
Warfarin is a widely prescribed oral anticoagulant used to
treat thromboembolic disorders (Rettie and Tai, 2006). Despite
more than 50 years of clinical experience, optimal warfarin
therapy remains challenging because of a narrow therapeutic
window and large interpatient differences in anticoagulant re-
sponse. Thus, the daily therapeutic warfarin dose varies by
more than an order of magnitude in a given population (Rettie
and Tai, 2006). The clinically available formulation of warfarin
is a racemic mixture, with the S-enantiomer having an esti-
mated 5-fold greater pharmacologic potency than the R-enan-
tiomer (Jonas and McLeod, 2009). (S)-Warfarin is eliminated
from the body almost exclusively via hepatic metabolism by
CYP2C9, with 7-hydroxylation representing the major meta-
bolic pathway (Jonas and McLeod, 2009). Accordingly, any pro-
cess that significantly impairs CYP2C9 activity would be ex-
pected to decrease the clearance of (S)-warfarin and increase
anticoagulant response. Indeed, a number of clinically used
CYP2C9 inhibitors, e.g., fluconazole, amiodarone, and tri-
methoprim/sulfamethoxazole, have been associated with seri-
ous bleeding events in patients receiving warfarin (Thi et al.,
2009).
Fig. 2. Inhibitory effects of selected flavonolignans on (S)-warfarin 7-hy-
droxylation activity in human liver microsomes. Human liver microsomes
(0.1 mg/ml) were incubated with (S)-warfarin (4 M) and flavonolignan
(1, 10, or 100 M; hatched, solid, and checkered bars, respectively) for 30
min. Reactions were initiated by the addition of NADPH (1 mM). (S)-
Warfarin 7-hydroxylation activity in the presence of vehicle control
(0.75% methanol, v/v) was 5.8 
 0.1 pmol/min/mg microsomal protein.
Bars and error bars denote means and S.D., respectively, of triplicate
incubations. , p  0.05 versus flavonolignan at 10 M; #, p  0.05 versus
flavonolignan at 1 M (two-way ANOVA, followed by Tukey’s test).
TABLE 1
Comparison of IC50 values for four key flavonolignans from milk thistle using (S)-warfarin 7-hydroxylation as an index of CYP2C9 activity




Silybin A Silybin B Isosilybin A Isosilybin B
M
Reversible inhibition experimental design
HLMs 18 
 2.2 8.2 
 1.4a 100 74 
 11
CYP2C9*1 12 
 0.9 6.7 
 0.5a N.D. N.D.
CYP2C9*2 19 
 1.7 9.3 
 0.9a N.D. N.D.
CYP2C9*3 9.3 
 2.0b 2.4 
 0.6a,b N.D. N.D.
IC50 shift experimental design
HLMs (NADPH)c 18 
 0.7 7.8 
 0.5 N.D. N.D.
HLMs (NADPH)d 17 
 0.7 7.9 
 0.9 N.D. N.D.
N.D., not determined.
a Significantly different from the IC50 for silybin A (p  0.05, Student’s t test of two independent samples).
b Significantly different from the IC50 obtained with HLMs, CYP2C9*1, and CYP2C9*2 (p  0.05, one-way ANOVA, followed by Tukey’s test) for a given inhibitor.
c NADPH was absent during the primary incubation.
d NADPH was present during the primary incubation.
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Whereas specific drugs have been identified as CYP2C9
inhibitors, such is not the case for herbal products, which
continue to increase in popularity as complementary and
alternative medicines for health maintenance, disease pre-
vention, and even disease treatment (Ulbricht et al., 2008).
The fact that herbal products are derived from natural
sources has led to the widespread notion that they are safe.
Hence, these products often are taken with conventional
medications, raising the potential for dangerous drug-herb
interactions. Moreover, unlike most drug products, herbal
products typically contain multiple bioactive ingredients that
vary in composition between batches and manufacturers,
precluding between-study comparisons, as well as accurate
predictions of drug interaction liability (Paine and Oberlies,
2007). A recent dose escalation study involving prostate can-
cer patients showed that oral gram doses of a crude/semipu-
rified extract of milk thistle, silibinin (2.5–20 g/day), were
well tolerated with minimal side effects; based on these en-
couraging results, a phase II study is underway (Flaig et al.,
2007; Kroll et al., 2007; Post-White et al., 2007). Taken to-
gether, the goal of the current work was to characterize,
systematically, the CYP2C9 inhibition properties of single
constituents from milk thistle. Based on previous studies
that compared the antiproliferative effects of individual fla-
vonolignans in prostate cancer cell lines and to discern
whether changes in stereo- and regiochemistry alter meta-
bolic inhibition, four key flavonolignans (silybin A, silybin B,
isosilybin A, and isosilybin B) were selected for evaluation.
Similar to the differential effects of individual flavonolig-
nans observed in prostate cancer cell models (Davis-Searles
Fig. 3. Dixon plots showing the inhibition of (S)-warfarin 7-hydroxylation by silybin A (A) and silybin B (B) in HLMs. HLMs (0.1 mg/ml) were incubated with
(S)-warfarin (1–15 M) and flavonolignan (1–80 M silybin A or 1–50 M silybin B) for 30 min. Reactions were initiated by the addition of NADPH (1 mM).
Symbols denote means of duplicate incubations. Solid lines denote regression lines through values generated from a simple mixed-type inhibition model
using WinNonlin (version 5.0.1).
Fig. 4. Inhibitory effects of silybin A and silybin B on (S)-warfarin
7-hydroxylation activity in recombinant CYP2C9 enzymes. Recombinant
enzymes (12.5 pmol/ml) were incubated with (S)-warfarin (4 M) and a
range of concentrations (1–100 M) of silybin A (f) or silybin B (Œ) for 30
(CYP2C9*1 and CYP2C9*2) or 60 (CYP2C9*3) min. Reactions were ini-
tiated by the addition of NADPH (1 mM). (S)-Warfarin 7-hydroxylation
activity in the presence of vehicle control (0.75% methanol, v/v) was,
respectively, 15 
 1.3, 8.0 
 0.4, and 3.6 
 0.3 pmol/min/nmol of recom-
binant enzyme. Symbols and error bars denote means and S.D., respec-
tively, of triplicate incubations. Solid (silybin A) and dashed (silybin B)
curves denote nonlinear least-squares regression of observed values us-
ing WinNonlin (version 5.0.1).
Fig. 5. IC50 shift plot for silybin A and silybin B. Human liver microsomes
(0.1 mg/ml) were incubated first with silybin A (squares) or silybin B
(triangles) (0.1–1000 M) in the presence (closed symbols) or absence
(open symbols) of NADPH (1 mM). The primary reaction mixture was
diluted 10-fold to initiate the secondary reaction, which contained
NADPH (1 mM) and (S)-warfarin (4 M). (S)-Warfarin 7-hydroxylation
activity in the presence of vehicle control (0.75% methanol, v/v) was 1.5
and 1.6 pmol/min/mg microsomal protein in the absence and presence,
respectively, of NADPH. The inset depicts the effects of the known
CYP2C9 mechanism-based inhibitor, tienilic acid (circles) (1–500 M).
Symbols denote means of duplicate incubations. Open symbols denote
observed values when NADPH was absent from the primary reaction
mixture; solid symbols denote observed values when NADPH was present
in the primary reaction mixture. Curves denote nonlinear least-squares
regression of observed values using WinNonlin (version 5.0.1).
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et al., 2005), individual flavonolignans differentially inhib-
ited the 7-hydroxylation of (S)-warfarin. Whereas isosilybin
A and isosilybin B were the most potent antiproliferative
compounds, silybin A and silybin B were the most potent
CYP2C9 inhibitors. Based on the greater than 4-fold differ-
ence in IC50 values between silybin A/silybin B and isosilybin
A/isosilybin B (20 M versus 70 M), the latter two
flavonolignans were not evaluated further. To determine the
mode of CYP2C9 inhibition by silybin A and silybin B, re-
versible inhibition design experiments that involved a range
of substrate and flavonolignan concentrations were under-
taken. The mixed-type model best described the data for both
compounds, producing Ki values of 4.8 and 10 M, respec-
tively. The lack of mechanism-based inhibition, as evidenced
from the IC50 shift experiments, is inconsistent with results
obtained by Sridar et al. (2004), who reported a Ki of 5 M
and a kinact of 0.14 min
1. These investigators used the
semipurified mixture, silibinin (termed silybin), a reconsti-
tuted enzyme system, and a fluorescent probe substrate, any
or all of which could account for this between-laboratory
discrepancy.
Xenobiotics, including drugs, herbal products, and dietary
substances, are considered to have a high drug interaction
liability when the ratio of in vivo inhibitor concentration to Ki
is greater than unity (Bachmann and Lewis, 2005). The av-
erage plasma and presumably total (i.e., bound  unbound)
concentrations of unconjugated silybin A/silybin B achieved
in the prostate cancer patient dose-escalation study (Flaig
et al., 2007) were at least 5-fold greater than the apparent Ki
values measured in the current work. It should be noted that
the systemic concentrations reported for these patients rep-
resented the sum of silybin A and silybin B. Although dosed
as a 1:1 mixture (i.e., silibinin), systemic concentrations
cannot be considered 1:1 due to differential clearance (Kroll
et al., 2007; Wen et al., 2008). Despite this limitation, the low
Ki values for both compounds compared with the high con-
centration of the mixture in plasma would necessitate cau-
tion when milk thistle products are taken with warfarin. The
potential interproduct variation in milk thistle constituents
in commercial products, along with the recent clinical study
involving losartan and a silymarin product further support
this contention.
Two common single nucleotide polymorphisms in the coding
region of the CYP2C9 gene, CYP2C9*2 (R144C) and CYP2C9*3
(I359L), are known to influence warfarin anticoagulant re-
sponse. Both of the corresponding proteins have lower catalytic
activity (approximately 50% and less than 10%, respectively)
compared with the protein encoded by the reference allele,
CYP2C9*1, and carriers of these variants often require a lower
daily dose of warfarin (Jonas and McLeod, 2009). CYP2C9*2
and CYP2C9*3 carriers also may require a longer period of time
to become stabilized on warfarin therapy (Rettie and Tai, 2006).
Consistent with previous reports, in the absence of inhibitor,
the velocities of 7-hydroxywarfarin formation with rCYP2C9*2
and rCYP2C9*3 were roughly 50 and 25%, respectively, of that of
rCYP2C9*1 (8.0, 3.6, and 15 pmol/min/nmol, respectively). Among
the different recombinant enzyme preparations, rCYP2C9*3 was
significantly more sensitive to inhibition by both silybin A and
silybin B. These observations, coupled with the increased time
to stabilize warfarin therapy and the increased bleeding risk
that is associated with this variant, may suggest that coadmin-
istration of warfarin and silymarin could further complicate
therapy in CYP2C9*3 carriers. Despite the increased sensitiv-
ity of rCYP2C9*3, the relatively potent inhibition potential of
these compounds toward rCYP2C9*1 and rCYP2C9*2 would
not exclude CYP2C9*1 and CYP2C9*2 carriers from being at
risk for a potential warfarin-milk thistle interaction.
In summary, unlike drug products, dietary/natural prod-
ucts are not consistently regulated and, accordingly, strict
preclinical or clinical testing is not required before market-
ing. Patients often take these products with their medica-
tions, sometimes unbeknownst to their physicians and/or
pharmacists, which can lead to potentially dangerous ad-
verse events. The current observations, combined with the
reported interaction between silymarin and losartan (Han
et al., 2009) and the interproduct variation in milk thistle
composition, prompts a clinical study with a standardized
milk thistle product and warfarin. Finally, the current
work provides an impetus to revisit cytochrome P450-me-
diated drug-milk thistle interactions using purified single
constituents.
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